Prof Cepko - Gensight Biologics Scientific Board
| SIGHT Stock | EUR 0.32 0.01 3.23% |
Insider
Prof Cepko is Scientific Board of Gensight Biologics SA
| Phone | 33 1 76 21 72 20 |
| Web | https://www.gensight-biologics.com |
Gensight Biologics Management Efficiency
The company has return on total asset (ROA) of (0.3876) % which means that it has lost $0.3876 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.719) %, meaning that it generated substantial loss on money invested by shareholders. Gensight Biologics' management efficiency ratios could be used to measure how well Gensight Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Regina Jehle | Abivax SA | N/A | |
| Pierre MBA | Abivax SA | N/A | |
| Irena Konstantinova | Inventiva SA | N/A | |
| Michele Robertson | DBV Technologies SA | N/A | |
| Pr Prasad | Nanobiotix SA | 78 | |
| Joseph Becker | DBV Technologies SA | N/A | |
| JeanPaul MD | Inventiva SA | N/A | |
| Kevin Trapp | DBV Technologies SA | 52 | |
| Michael Cooreman | Inventiva SA | 65 | |
| Eric LLM | Inventiva SA | 49 | |
| Prof Ehrlich | Abivax SA | N/A | |
| Elsa Borghi | Nanobiotix SA | N/A | |
| Jean Volatier | Inventiva SA | 59 | |
| Pierre Broqua | Inventiva SA | 61 | |
| Raquel Lizarraga | Abivax SA | N/A | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| AnneJuliette MA | Nanobiotix SA | 49 | |
| Pascal Wotling | DBV Technologies SA | N/A | |
| Kathryn McNeil | Nanobiotix SA | 48 | |
| Nathalie Harroy | Inventiva SA | 56 | |
| Frederic Cren | Inventiva SA | 57 | |
Management Performance
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 |
Gensight Biologics Leadership Team
Elected by the shareholders, the Gensight Biologics' board of directors comprises two types of representatives: Gensight Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gensight. The board's role is to monitor Gensight Biologics' management team and ensure that shareholders' interests are well served. Gensight Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gensight Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Serge Picaud, Scientific Board | ||
| Scott Jeffers, Chief Officer | ||
| Clothilde Caillet, Director Communication | ||
| Bernard Gilly, Chairman of the Board, CEO, Co-Founder | ||
| Pr Roska, Scientific Board | ||
| Thomas Gidoin, Chief Officer | ||
| JoseAlain MD, Vice Founder | ||
| Prof Cepko, Scientific Board |
Gensight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gensight Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (6.59) % | |||
| Current Valuation | 150.19 M | |||
| Shares Outstanding | 46.16 M | |||
| Shares Owned By Insiders | 12.75 % | |||
| Shares Owned By Institutions | 35.65 % | |||
| Price To Book | 50.99 X | |||
| Price To Sales | 33.81 X | |||
| Revenue | 5.28 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.